Location: Hammersmith
Reporting to: Director, Finance
Orchard Therapeutics is a global biotechnology gene therapy company dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative cell and gene therapies. Orchard has its global headquarters in London and is a wholly owned subsidiary of Kyowa Kirin, a Japan-based Global Specialty Pharmaceutical Company.
Reporting to the Director, Finance, the Associate Director, Finance, will play a key leadership role across both management accounting and financial reporting, ensuring a robust control environment and delivering high-quality financial insights to support business decision-making.
This role is responsible for leading the month-end close process, overseeing financial reporting and technical accounting and ensuring compliance with IRFS and internal policies. In parallel, the role serves as strategic finance business partner, driving FP&A activities including budgeting, forecasting and performance analysis across the organization.
The Associate Director will collaborate closely with cross-functional teams and external stakeholders to resolve complex finance and accounting issues, support planning cycles and ensure timely and accurate reporting. This is a highly visible position with broad impact across the finance function and the wider business.
Key Elements and Responsibilities
Requirements
Experience, Skills & Knowledge
Education

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment.
Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.
For more information, please visit https://www.orchard-tx.com/.